Compare Citius Pharmaceuticals Inc (CTXR) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Delta Air Lines, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Delta Air Lines, Inc. trades at $80.59 (market cap $54.02B). The key difference: Delta Air Lines, Inc. is far larger — about 3966.2× Citius Pharmaceuticals Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Delta Air Lines, Inc. for 97 Days on average.
| CTXR | DAL | |
|---|---|---|
Market Cap | $13.62M | $54.02B |
Volume | 132,438 | 9,632,845 |
Sector | Health | Industrials |
52-Week High | $1.82 | $93.66 |
52-Week Low | $0.48 | $55.65 |
Typical Hold Time | 16 Days | 97 Days |
Enterprise Value | $3.79M | $69.34B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Delta Air Lines (DAL) trades at $80.49, down 2.99% on the day, as technical indicators signal bearish momentum with the stock testing support near $80. Fundamentally, the company shows solid profitability with a 5.78% net margin and 20.12% ROE, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's in-flight internet instead of Starlink.
The investment outlook remains positive with strong analyst support (82% buy ratings) and a $103.36 consensus price target offering 28% upside. Key risks include fuel cost volatility, rising crew expenses, and competitive threats to premium customer retention. Cash flow trends show improvement with net positive flows since 2024.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
